Search Results - franchini

4 Results

Sort By:

Improved HIV Vaccines Through Ras Activation

Abstract: Researchers at the National Cancer Institute (NCI) have developed a new method of improving the efficacy of vaccines in patients with human immunodeficiency virus (HIV) by activating Ras. This method can be used to develop more efficacious vaccine compositions by activating Ras before, during, or after vaccination. Additionally, the researchers...

Published: 8/5/2024 | Inventor(s): Genoveffa Franchini, Rafick Sakaly, Slim Fourati, Mark Cameron, Monica Vaccari, Luca Schifanella, Shari Gordon, Melvin Doster, Namal Liyanage

Keywords(s): Franchini, HIV, Human Immunodeficiency Virus, immune response, RAS, Ras Pathway Activation

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease

High Efficacy Vaccine and Microbicide Combination For Use Against HIV

Abstract: Human immunodeficiency virus (HIV) remains a major global health challenge despite the advancement made in development of effective antiretrovirals (ARVs). ARVs are effective at limiting replication and spread of the virus, and progression to acquired immuno-deficiency syndrome (AIDS). However, ARVs often lead to emergence of drug-resistant...

Published: 8/5/2024 | Inventor(s): Genoveffa Franchini, Marjorie Robert-Guroff, Daniel Appella, Sabrina Helmold Hait, Mohammed Rahman, Massimiliano Bissa, Ettore Appella, Lisa Marie Jenkins, Isabela Silva De Castro

Keywords(s): Acquired Immuno-Deficiency Syndrome, ADCC, AIDS, Antibody-dependent Cellular Cytotoxicity, Efferocytosis, Envelope Glycoprotein 120, Envelope Variable Region, Franchini, gp120, HIV, Human Immunodeficiency Virus, Microbicide, SAMT-247, V1, Vaccine

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Application > Vaccines

Immunogens for Use in a High Efficacy HIV Vaccine

Abstract: Human immunodeficiency virus (HIV) infections remain a pandemic, most prevalent in Africa and the Americas. Anti-retroviral treatments have been effective in preventing spread of the virus and active outbreaks of acquired immune deficiency syndrome (AIDS). However, the development and deployment of an effective vaccine would provide long-lasting...

Published: 8/14/2024 | Inventor(s): Genoveffa Franchini, Timothy Cardozo, Isabela Silva De Castro, Giacomo Gorini, Massimiliano Bissa, Manuel Becerra-Flores

Keywords(s): AIDS, Franchini, GLYCOPROTEIN, gp120, HIV, Human Immunodeficiency Virus, V1, V2, Vaccine, Variable Envelope Region

Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines

Enhanced Immunogenicity Against HIV-1 Using a DNA-prime Poxvirus Vaccination

Abstract: Researchers at the National Cancer Institute (NCI) have developed a method of stimulating an immune response in humans at risk for infection by, or already infected with, an Human Immunodeficiency Virus (HIV)-1 retrovirus. This method utilizes deoxyribonucleic acid (DNA) vaccines to stimulate CD8+ T cell immune responses. The DNA vaccine encodes...

Published: 8/5/2024 | Inventor(s): Genoveffa Franchini, Zdenek Hel, George Pavlakis, James Tartaglia

Keywords(s): Combination Therapy, CTL, cytotoxic T lymphocyte, Deoxyribonucleic Acid, DNA vaccine, Franchini, HIV, Human Immunodeficiency Virus, POX VIRUS

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, Application > Vaccines